📋 About: Dimerix Limited (ASX:DXB) is a biotech company that has developed a treatment for inflammatory diseases - such as kidney and respiratory diseases.

🌏 Macro Theme: After watching the COVID-19 pandemic unfold and the global attention on vaccine development, we believe the next decade will see significant investor interest in life sciences, human health and bio-technology.

FSGS Treatment (Main Bet)

FSGS is a rare kidney disease, DXB's treatment has acquired "orphan stats" which means that it is eligible for emergency use approvals. DXB will undertake Phase III clinical trials to evaluate whether their drug is an effective and safe treatment against the disease.

last updated 26-Aug-2021

✅ Phase III Study Design Complete
✅ Study design approval from FDA
🔄 Ethics submission and site initiation for first sites
🔲 Phase III Trials Commenced: Study Period 1
🔲 First patient Recruited/Dosed
🔲 Patient Recruitment Update 1 - 1 patient to be recruited
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 Recruitment Complete
🔲 Interim Results
🔲 Phase III Trials Continue: Study Period 2
🔲 Patient Recruitment Update 1
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 Phase III Data collected for accelerate approvals
🔲 Accelerate Approvals Submitted
🔲 Accelerated Approvals Granted (H2 2024)
🔲 Drug Commercialised
🔲 Final Results eGFR (how well is the patient’s kidney functioning)
🔲 New Milestones Added

Covid-19 Treatment (Side Bet 1)

The Clarity 2.0 Study will evaluate whether DXB’s drug DMX-200 will be able to treat patients diagnosed with COVID-19 who are intended for hospital admission.

✅Study Announced
✅ Ethics Approval
🔄 Regulatory approval by DCGI
🔄 Patient Recruitment Update 1
🔲 Safety Threshold Met (80 Patients)
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 CLARITY Phase III Study Complete
🔲 Primary Endpoint Reporting
🔲 Emergency use granted
🔲 Drug Commercialised
🔲 New Milestones Added

Covid-19 Treatment (Side Bet 2)

The Covid REMAP Study will evaluate whether DXB's treatment DMX-200 will be able to help COVID-19 ICU Patients with Pneumonia.

✅ Patient Recruitment Commenced
✅ Study Commenced
🔲 Patient Recruitment Update 2
🔲 Patient Recruitment Update 3
🔲 REMAP-CAP Phase III Study Complete
🔲 Primary Endpoint Reporting
🔲 Emergency use granted
🔲 Drug Commercialised

Dimerix Corporate Milestones

✅ $20M Cap Raise @20c
✅ Investment from Biotech Fund Merchant
✅ Portfolio initiation
🔲 Funding 1
🔲 Funding 2
🔲 Unexpected Positive Announcement 1
🔲 Unexpected Positive Announcement 2
🔲 Unexpected Positive Announcement 3
🔲 New Technology Development 1
🔲 New Technology Development 2

Investment Milestones for DXB

✅ Initial Investment: @20c
🔲 Increase Investment
🔲 Increase Investment
🔲 Price increases 500% from initial entry
🔲 Price increases 1000% from initial entry
🔲 Price increases 2000% from initial entry
🔲 12 Month Capital Gain Discount
🔲 Free Carry
🔲 Take Profit
🔲 Hold remaining Position for next 2+ years

”Expected Company Milestones” are based on the company's publicly available execution plan and some assumptions made by our team on potential announcements that should de-risk the investment. “Our investment milestones” show our current long-term investment plan. Early stage investments are risky and there is no guarantee that the expected events will occur. The lists are not in sequential order.

Key

🔲 Expected Milestone
✅ Achieved Milestone
🟩 Above Average Result
🟨 Average (Expected) Result
🟧 Below Average Result
🟥 Negative Result
🌎 Macro Event
⚔️ Results from Other Company / Project
🔄 Progress Ongoing
[UPA] Unexpected Positive Announcement
[NEW] New Milestone Added